Molecular targets on mast cells and basophils for novel therapies.
Kuopio, Finland. In J Allergy Clin Immunol, 2014
Surface-activating receptors, such as CD48 and thymic stromal lymphopoietin receptors, as well as inhibitory receptors, such as CD300a, FcγRIIb, and endocannabinoid receptors, hold promising therapeutic possibilities based on preclinical studies.
Role of phosphatidylserine receptors in enveloped virus infection.
Los Angeles, United States. In J Virol, 2014
In this study, we examined most of the known human phosphatidylserine-recognizing molecules, including MFG-E8, TIM-1, -3, and -4, CD300a, BAI1, and stabilin-1 and -2, for their abilities to facilitate virus binding and infection.
PPARβ/δ activation of CD300a controls intestinal immunity.
Tokyo, Japan. In Sci Rep, 2013
Here, we show that PPARβ/δ (peroxisome proliferator-activated receptor β/δ) directly regulates CD300a in macrophages that express the immunoreceptor tyrosine based-inhibitory motif (ITIM)-containing receptor.
Are we ready to downregulate mast cells?
Jerusalem, Israel. In Curr Opin Immunol, 2009
Human MCs (hMCs) have been recently shown to express the death receptor (DR) TRAIL and the inhibitory receptors (IRs) CD300a and Siglec-8.